In 2016 total depreciation, amortization, and impairment losses amount to € 1,302 million, made up of:

  • straight-line depreciation and amortization of € 1,026 million for continuing operations including:
    • cost of goods sold (€ 614 million);
    • administrative and commercial costs (€ 103 million);
    • research and development costs (€ 54 million);
    • other (€ 256 million), including € 231 million for Rhodia and Cytec PPA amortization (see note F3 Other operating gains and losses);
  • net impairment loss of € 143 million for continuing operations;
  • impairment loss of Solvay Indupa of € 63 million; and
  • 70 million for discontinued operations, including € 11 million for Rhodia PPA amortization.

In 2015 total depreciation, amortization, and impairment losses amount to € 978 million, made up of:

  • straight-line depreciation and amortization of € 772 million for continuing operations including:
    • cost of goods sold (€ 515 million);
    • administrative and commercial costs (€ 97 million);
    • research and development costs (€ 39 million);
    • other (€ 120 million), including € 98 million for Rhodia PPA amortization (see note F3 Other operating gains and losses);
  • net impairment loss of € 48 million for continuing operations;
  • impairment loss of Solvay Indupa of € 88 million at year end; and
  • 71 million for discontinued operations, including € 11 million for Rhodia PPA amortization.